| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Target: Lipid nanoparticles (LNP) formulation excipient. This compound is a synthetic lipid/lipidoid used as a component of lipid nanoparticles for nucleic acid delivery. It enhances the solubility and interaction with lipid membranes due to its amphiphilic nature, allowing it to interact with both hydrophilic and hydrophobic environments. It does not have a specific biological target; it is a formulation excipient.
|
|---|---|
| ln Vitro |
In vitro, 1265904-26-4 is used in the formulation of lipid nanoparticles (LNPs) that encapsulate therapeutic nucleic acids (mRNA, siRNA, pDNA). LNPs containing this lipidoid show efficient cellular uptake, endosomal escape, and delivery of cargo to the cytoplasm. No direct biological activity (cell viability, enzyme inhibition) is reported; activity is assessed as delivery efficiency.
|
| ln Vivo |
In vivo, LNPs formulated with 1265904-26-4 have been used to deliver nucleic acid therapeutics (e.g., mRNA for protein replacement therapy, siRNA for gene silencing). After intravenous or intramuscular administration, LNPs accumulate in the liver (for IV) or at the injection site, release the cargo into target cells, and result in functional protein expression or target gene silencing. No published data specifically for this compound are available.
|
| Enzyme Assay |
For cell-free assays (LNP characterization): 1265904-26-4 is dissolved in ethanol at 1-10 mg/mL. Mix with other lipid components (e.g., DSPC, cholesterol, DMG-PEG2000) in organic solvent. Prepare LNP by microfluidic mixing or thin-film hydration. LNP particle size (60-120 nm) and polydispersity index (PDI <0.2) are measured by dynamic light scattering (DLS). Encapsulation efficiency (>90%) is measured by RiboGreen assay. Cryo-TEM imaging is performed for morphological assessment. No specific biological assays.
|
| Cell Assay |
For cell-based assays: HEK293T, HeLa, or primary hepatocytes are seeded in 96-well plates. LNPs encapsulating reporter mRNA (e.g., Luciferase or GFP mRNA) or siRNA (e.g., targeting GFP or luciferase) are added to cells at various concentrations (0.1-10 ug/mL total lipid). After 24-48 h, luciferase activity (using luciferin substrate) or GFP fluorescence is measured. Knockdown efficiency for siRNA is measured by qPCR. Cytotoxicity is assessed by MTT or CellTiter-Glo assay. No published data specifically for this compound.
|
| Animal Protocol |
For in vivo animal studies: mice (Balb/c, C57BL/6) are administered LNPs formulated with 1265904-26-4 via intravenous tail vein injection (for liver-targeted delivery) or intramuscular injection (for vaccine delivery). For mRNA-LNP studies, plasma and tissues (liver, spleen) are collected 6-24 h post-dose, and luciferase activity (if using luciferase mRNA) is measured by IVIS imaging or homogenate luminescence. For siRNA-LNP, target gene mRNA levels are measured by qPCR 48-72 h post-dose. For vaccine studies, antibody titers are measured by ELISA. No published data specifically for this compound.
|
| ADME/Pharmacokinetics |
PK properties of 1265904-26-4: As a lipid component of LNPs, the PK is determined by the nanoparticle formulation, not by the free lipid. LNPs typically have a plasma half-life of 2-12 h in rodents, with rapid clearance by the reticuloendothelial system (RES) (liver, spleen). The lipidoid is metabolized and excreted over days to weeks. The compound itself is not studied as a free drug. No formal PK data are available.
|
| Toxicity/Toxicokinetics |
No toxicity data have been reported specifically for 1265904-26-4. Lipid/lipidoid components in LNPs are generally well-tolerated at typical doses (0.1-1 mg/kg total lipid in mice). Potential toxicities include transient ALT/AST elevations (hepatotoxicity), complement activation-related pseudoallergy (CARPA), and inflammatory responses (cytokine release). The compound is for research use only and not for human administration.
|
| References | |
| Additional Infomation |
1265904-26-4 is a research reagent, not a drug. It is not FDA-approved for clinical use. It is used in lipid nanoparticle formulation development for nucleic acid delivery (mRNA vaccines, siRNA therapeutics, gene editing). The lipidoid is an essential component for ensuring efficient encapsulation, cellular uptake, and endosomal escape. Its amphiphilic nature makes it suitable for applications in drug delivery systems, including nanomedicine and genetic medicine.
|
| Molecular Formula |
C56H116N4O4
|
|---|---|
| Molecular Weight |
909.54
|
| Exact Mass |
908.899
|
| CAS # |
1265904-26-4
|
| PubChem CID |
163408759
|
| Appearance |
Light yellow to orange solid powder
|
| LogP |
17.8
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
50
|
| Heavy Atom Count |
64
|
| Complexity |
795
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(O)(CCCCCCCCCC)CN(CCN1CCN(CCN(CC(O)CCCCCCCCCC)CC(CCCCCCCCCC)O)CC1)CC(O)CCCCCCCCCC
|
| InChi Key |
RMEBVAKPPHPOQS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C56H116N4O4/c1-5-9-13-17-21-25-29-33-37-53(61)49-59(50-54(62)38-34-30-26-22-18-14-10-6-2)47-45-57-41-43-58(44-42-57)46-48-60(51-55(63)39-35-31-27-23-19-15-11-7-3)52-56(64)40-36-32-28-24-20-16-12-8-4/h53-56,61-64H,5-52H2,1-4H3
|
| Chemical Name |
1-[2-[4-[2-[bis(2-hydroxydodecyl)amino]ethyl]piperazin-1-yl]ethyl-(2-hydroxydodecyl)amino]dodecan-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~27.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0995 mL | 5.4973 mL | 10.9946 mL | |
| 5 mM | 0.2199 mL | 1.0995 mL | 2.1989 mL | |
| 10 mM | 0.1099 mL | 0.5497 mL | 1.0995 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
